Recurrent or Metastatic Nasopharyngeal Carcinoma Clinical Trial
An Open-Label, Non-randomized, Multi-Center Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with recurrent metastatic nasopharyngeal carcinoma.
The study consists of two stages. In Part A, approximately 24 patients will be enrolled to evaluate the safety and preliminarily efficacy of MRG003. If the prespecified criteria are met in Part A, this study will enter Part B seamlessly to further evaluate the efficacy and safety of MRG003. There are two cohorts in Part B, including approximately 79 patients who have failed the first line standard of care (SOC) in Cohort 1 and approximately 48 patients who have failed at least two lines of chemotherapy and/or immunotherapy. ;